DIVE INTO DIALYSIS: NxStage Aims To Transform Home Hemodialysis Into $2bn Market
This article was originally published in Clinica
For the second part of Clinica’s three-part special series on the dialysis market, Reed Miller talked to the CEO of NxStage Medical, a Massachusetts-based company that markets the NxStage System One, which the firm touts as the only “truly portable” hemodialysis system FDA-cleared for home hemodialysis and home nocturnal hemodialysis. As the company is set to face competition for home hemodialysis customers from upstarts like Quanta, profiled in part 1 of this series, and giants like Fresenius Medical Care, the subject of part 3, NxStage is planning to use home hemodialysis as a “beachhead” to invade other, more lucrative markets
You may also be interested in...
The UK company recently finished a pilot trial of the SC+ personal dialysis system in France, as part of its plan to launch it in Europe by the end of 2018 and earn US FDA clearance in 2019.
End-stage renal disease (ESRD) affects 600,000 Americans, striking over 120,000 people a year, and most of these patients require renal replacement therapy, such as hemodialysis. For most, that means a several-hour treatment, three times a week, at a dedicated outpatient center run by a service company like DaVita, Inc., or Fresenius Medical Care. But getting dialyzed at home is another option. Just under 2% of patients do home hemodialysis (HHD) today, but a growing number of companies are betting that this number could increase substantially.
In a move to expand its dialysis empire into the growing home hemodialysis and critical care markets, Fresenius Medical Care has inked a $2bn deal to acquire NxStage Medical.